Corvus Pharmaceuticals (FRA:C17) Other Financing: €1.16 Mil (TTM As of Mar. 2026)


FRA:C17 Corvus Pharmaceuticals Inc FRA:C17
34 GF Score
Price €12.94
! 1 Warning Sign
View Full Analysis

What is Corvus Pharmaceuticals Other Financing?

Corvus Pharmaceuticals FRA:C17 -2.41% 34 Other Financing is €1.16 Mil as of Mar. 2026. GuruFocus rates FRA:C17 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Corvus Pharmaceuticals's Other Financing for the three months ended in Mar. 2026 was €1.16 Mil.

Corvus Pharmaceuticals's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €1.16 Mil.

Corvus Pharmaceuticals Other Financing Historical Data

* Premium members only.

The historical data trend for Corvus Pharmaceuticals's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corvus Pharmaceuticals Other Financing Chart

Corvus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.08 0.00 0.01 31.16 0.00

Corvus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.16
FRA:C17
34GF Score
Corvus Pharmaceuticals Inc FRA:C17
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corvus Pharmaceuticals Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €1.16 Mil mean?
Corvus Pharmaceuticals (FRA:C17) has a Other Financing of €1.16 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Corvus Pharmaceuticals and its competitors.
Is Corvus Pharmaceuticals' Other Financing too high?
Corvus Pharmaceuticals' current Other Financing is €1.16 Mil. Overall, Corvus Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Corvus Pharmaceuticals' Other Financing compare to LXRX and CGEM?
Corvus Pharmaceuticals' Other Financing of €1.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Corvus Pharmaceuticals and its competitors. Corvus Pharmaceuticals's current Other Financing is €1.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corvus Pharmaceuticals stock overvalued right now?
Corvus Pharmaceuticals (FRA:C17) has a current Other Financing of €1.16 Mil. The current Other Financing is €1.16 Mil. Corvus Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Corvus Pharmaceuticals (FRA:C17), the current Other Financing is €1.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corvus Pharmaceuticals Business Description

Other Exchanges CRVS:USAC17:Germany
Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
34GF Score

Get the complete analysis for FRA:C17

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.94
Price